Key Details
Price
$5.12Annual EPS
-$1.07Annual ROE
-817.78%Beta
1.64Events Calendar
Next earnings date:
Mar 21, 2025Recent quarterly earnings:
Nov 08, 2024Recent annual earnings:
Mar 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120767&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Jan. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline.
LOS ANGELES, CA / ACCESSWIRE / January 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120671&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024 inclusive (the "Class Period").
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120726&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
NEW YORK, NY / ACCESSWIRE / January 4, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120647&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 4, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=120630&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / January 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.
FAQ
- What is the primary business of Humacyte?
- What is the ticker symbol for Humacyte?
- Does Humacyte pay dividends?
- What sector is Humacyte in?
- What industry is Humacyte in?
- What country is Humacyte based in?
- When did Humacyte go public?
- Is Humacyte in the S&P 500?
- Is Humacyte in the NASDAQ 100?
- Is Humacyte in the Dow Jones?
- When was Humacyte's last earnings report?
- When does Humacyte report earnings?
- Should I buy Humacyte stock now?